Total Payments
$25,745
2024 Payments
$353.57
Companies
41
Transactions
272
Medicare Patients
3,343
Medicare Billing
$362,136
Payment Breakdown by Category
Other$10,025 (38.9%)
Research$7,239 (28.1%)
Food & Beverage$5,683 (22.1%)
Consulting$1,490 (5.8%)
Travel$1,169 (4.5%)
Education$138.06 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,025 | 5 | 38.9% |
| Unspecified | $7,239 | 3 | 28.1% |
| Food and Beverage | $5,683 | 246 | 22.1% |
| Consulting Fee | $1,490 | 4 | 5.8% |
| Travel and Lodging | $1,169 | 4 | 4.5% |
| Education | $138.06 | 10 | 0.5% |
Payments by Type
General
$18,506
269 transactions
Research
$7,239
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $11,320 | 45 | $0 (2024) |
| Eli Lilly and Company | $7,239 | 3 | $0 (2021) |
| Novo Nordisk AS | $2,164 | 16 | $0 (2019) |
| Lilly USA, LLC | $1,171 | 4 | $0 (2020) |
| Novo Nordisk Inc | $899.28 | 44 | $0 (2024) |
| PFIZER INC. | $432.33 | 27 | $0 (2022) |
| Kowa Pharmaceuticals America, Inc. | $319.63 | 29 | $0 (2022) |
| ARBOR PHARMACEUTICALS, INC. | $294.76 | 15 | $0 (2019) |
| Alnylam Pharmaceuticals Inc. | $233.95 | 10 | $0 (2022) |
| Amgen Inc. | $183.64 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $353.57 | 16 | Novo Nordisk Inc ($104.50) |
| 2023 | $124.28 | 6 | Novo Nordisk Inc ($74.22) |
| 2022 | $489.05 | 27 | Novo Nordisk Inc ($236.77) |
| 2021 | $1,089 | 39 | Novo Nordisk Inc ($297.91) |
| 2020 | $7,335 | 24 | Eli Lilly and Company ($6,945) |
| 2019 | $3,447 | 42 | Boehringer Ingelheim Pharmaceuticals, Inc. ($2,417) |
| 2018 | $8,533 | 60 | Boehringer Ingelheim Pharmaceuticals, Inc. ($5,204) |
| 2017 | $4,374 | 58 | Boehringer Ingelheim Pharmaceuticals, Inc. ($3,550) |
All Payment Transactions
272 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/11/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: Not Applicable | ||||||
| 10/01/2024 | Vital Connect, Inc | VITALPATCH RTM (Device) | Food and Beverage | In-kind items and services | $15.98 | General |
| Category: CARDIOLOGY | ||||||
| 09/09/2024 | Vital Connect, Inc | VITALPATCH RTM (Device) | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: CARDIOLOGY | ||||||
| 07/18/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $19.79 | General |
| Category: Heart Failure and Hypertension | ||||||
| 06/25/2024 | Abbott Laboratories | MITRACLIP (Device) | Food and Beverage | In-kind items and services | $24.66 | General |
| Category: Vascular | ||||||
| 06/13/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $16.02 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/23/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: Obesity | ||||||
| 05/21/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $26.87 | General |
| Category: Heart Failure and Hypertension | ||||||
| 03/25/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: Not Applicable | ||||||
| 03/20/2024 | Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor (Device) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Cardiac Arrhythmia Monitoring | ||||||
| 03/18/2024 | Novo Nordisk Inc | Wegovy (Drug) | Education | In-kind items and services | $32.27 | General |
| Category: Obesity | ||||||
| 03/18/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: Diabetes | ||||||
| 03/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: DIABETES | ||||||
| 02/12/2024 | Medicure Pharma Inc. | Zypitamag (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $30.22 | General |
| Category: Cardiology | ||||||
| 02/08/2024 | Novo Nordisk Inc | Wegovy (Drug) | Education | In-kind items and services | $32.27 | General |
| Category: Obesity | ||||||
| 02/07/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: Cardiology | ||||||
| 11/27/2023 | Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor (Device) | Food and Beverage | In-kind items and services | $20.44 | General |
| Category: Cardiac Arrhythmia Monitoring | ||||||
| 11/15/2023 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: Diabetes | ||||||
| 09/13/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $29.62 | General |
| Category: DIABETES | ||||||
| 07/25/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $24.64 | General |
| Category: Diabetes | ||||||
| 06/26/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.40 | General |
| Category: Diabetes | ||||||
| 01/09/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: Diabetes | ||||||
| 12/19/2022 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $21.71 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/12/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $10.33 | General |
| Category: Diabetes | ||||||
| 11/16/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $12.10 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $7,239 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 454 | 685 | $211,026 | $48,956 |
| 2022 | 14 | 779 | 1,223 | $351,245 | $83,323 |
| 2021 | 10 | 811 | 1,139 | $376,401 | $87,748 |
| 2020 | 14 | 1,299 | 1,808 | $657,775 | $142,107 |
Total Patients
3,343
Total Services
4,855
Medicare Billing
$362,136
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 126 | 258 | $70,950 | $24,104 | 34.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 62 | 68 | $61,200 | $9,769 | 16.0% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 37 | 60 | $27,000 | $5,512 | 20.4% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 50 | 55 | $27,500 | $3,027 | 11.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 36 | $6,660 | $2,045 | 30.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 14 | $5,250 | $1,832 | 34.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 100 | 143 | $8,185 | $1,545 | 18.9% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 13 | 28 | $4,051 | $929.43 | 22.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 21 | 23 | $230.00 | $193.20 | 84.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 144 | 356 | $97,975 | $32,732 | 33.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 98 | 112 | $100,800 | $16,940 | 16.8% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2022 | 55 | 96 | $43,200 | $8,457 | 19.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 95 | 139 | $25,715 | $7,187 | 27.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 24 | $9,000 | $3,205 | 35.6% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2022 | 55 | 60 | $30,000 | $3,180 | 10.6% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2022 | 40 | 71 | $7,100 | $3,054 | 43.0% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 35 | 56 | $7,000 | $2,190 | 31.3% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2022 | 11 | 11 | $8,800 | $1,596 | 18.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 95 | 140 | $7,285 | $1,535 | 21.1% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2022 | 31 | 46 | $6,900 | $1,459 | 21.1% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2022 | 24 | 25 | $4,650 | $1,166 | 25.1% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2022 | 30 | 30 | $2,250 | $454.76 | 20.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 47 | 57 | $570.00 | $168.66 | 29.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 173 | 343 | $94,325 | $31,523 | 33.4% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 119 | 131 | $117,900 | $20,611 | 17.5% |
About Dr. Winston Gandy, MD
Dr. Winston Gandy, MD is a Cardiovascular Disease healthcare provider based in Alpharetta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1760481477.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Winston Gandy, MD has received a total of $25,745 in payments from pharmaceutical and medical device companies, with $353.57 received in 2024. These payments were reported across 272 transactions from 41 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($10,025).
As a Medicare-enrolled provider, Gandy has provided services to 3,343 Medicare beneficiaries, totaling 4,855 services with total Medicare billing of $362,136. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Alpharetta, GA
- Active Since 07/15/2005
- Last Updated 01/14/2024
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1760481477
Products in Payments
- PRADAXA (Drug) $6,678
- JARDIANCE (Drug) $5,799
- Ozempic (Drug) $493.05
- Livalo (Drug) $319.63
- ONPATTRO (Drug) $233.95
- ELIQUIS (Drug) $224.19
- Rybelsus (Drug) $170.29
- Corlanor (Drug) $131.81
- Bidil (Drug) $118.50
- Adempas (Drug) $116.60
- CHANTIX (Drug) $113.80
- VERQUVO (Drug) $106.39
- VIAGRA (Drug) $88.75
- Edarbyclor (Drug) $88.19
- Edarbi (Drug) $88.07
- Wegovy (Drug) $87.10
- Solia (Device) $82.87
- BYSTOLIC (Drug) $82.00
- LifeVest (Device) $77.60
- FFRct (Device) $61.06
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Alpharetta
Jason Reingold, M.d, M.D
Cardiovascular Disease — Payments: $209,039
Cardiovascular Disease $209,039
Randy Turkel, M.d, M.D
Cardiovascular Disease — Payments: $6,539
Cardiovascular Disease $6,539
Dr. John Attokaren, M.d, M.D
Cardiovascular Disease — Payments: $2,703
Cardiovascular Disease $2,703
Chung Yoon, M.d, M.D
Cardiovascular Disease — Payments: $1,562
Cardiovascular Disease $1,562
Marlene Blaise, Md, MD
Cardiovascular Disease — Payments: $398.12
Cardiovascular Disease $398.12